We are live on
!
Find out more
RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$1.06B
1-Year Est. Return
52.03%
This Fund
S&P 500
This Quarter
Est. Return
+8.21%
1 Year Est. Return
+52.03%
3 Year Est. Return
+131.18%
5 Year Est. Return
+187.67%
10 Year Est. Return
+1,140.82%
AUM
$337M
AUM Growth
+$3.84M
(+1.2%)
Cap. Flow
-$17.9M
Cap. Flow
% of AUM
-5.32%
Top 10 Holdings %
Top 10 Hldgs %
34.36%
Holding
109
New
18
Increased
35
Reduced
37
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$9.48M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$7.12M |
| 3 |
Cardinal Health
CAH
|
+$6.74M |
| 4 |
AGN
Allergan plc
AGN
|
+$5.18M |
| 5 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$4.64M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$11.3M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$9.87M |
| 3 |
Gilead Sciences
GILD
|
+$5.35M |
| 4 |
CFNL
Cardinal Financial Corp
CFNL
|
+$5.03M |
| 5 |
FRX
FOREST LABORATORIES INC
FRX
|
+$4.44M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.2% |
| 2 | Miscellaneous | 9.78% |
| 3 | Financials | 1.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Biogen
BIIB
$32.2B
| $15.8M | 4.68% |
50,000
+8,952
| +22% | +$2.69M |
|
|
COV
2
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
| $15.4M | 4.58% |
171,000
+126,779
| +287% | +$9.48M |
|
|
3
Gilead Sciences
GILD
$185B
| $14.9M | 4.43% |
180,000
-68,735
| -28% | -$5.35M |
|
|
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
| $14.5M | 4.31% |
93,000
-18,731
| -17% | -$2.96M |
|
|
CELG
5
DELISTED
Celgene Corp
CELG
| $13.5M | 4% |
156,781
+39,999
| +34% | +$3.04M |
|
|
6
Vertex Pharmaceuticals
VRTX
$130B
| $9.62M | 2.85% |
+101,600
| New | +$7.12M |
|
7
BioMarin Pharmaceuticals
BMRN
$12.7B
| $9.33M | 2.77% |
150,000
+4,736
| +3% | +$286K |
|
8
Alkermes
ALKS
$7.81B
| $8.46M | 2.51% |
168,000
-33,277
| -17% | -$1.53M |
|
9
Incyte
INCY
$25.6B
| $7.51M | 2.23% |
133,000
+25,962
| +24% | +$1.33M |
|
|
10
Cardinal Health
CAH
$53B
| $6.79M | 2.01% |
+99,000
| New | +$6.74M |
|
|
AGN
11
DELISTED
Allergan Inc
AGN
| $6.77M | 2.01% |
40,000
+12,484
| +45% | +$1.94M |
|
|
12
Regeneron Pharmaceuticals
REGN
$80.5B
| $6.36M | 1.89% |
22,500
-33,292
| -60% | -$9.87M |
|
|
AGN
13
DELISTED
Allergan plc
AGN
| $5.58M | 1.65% |
+25,000
| New | +$5.18M |
|
|
SLXP
14
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
| $5.37M | 1.59% |
43,493
-10,295
| -19% | -$1.14M |
|
15
Boston Scientific
BSX
$62.7B
| $5.3M | 1.57% |
415,000
+130,022
| +46% | +$1.69M |
|
16
Acadia Pharmaceuticals
ACAD
$4.73B
| $5.2M | 1.54% |
230,000
+53,117
| +30% | +$1.11M |
|
17
Cigna
CI
$73.6B
| $5.06M | 1.5% |
55,000
+5,865
| +12% | +$503K |
|
|
PCYC
18
DELISTED
PHARMACYCLICS INC
PCYC
| $4.93M | 1.46% |
55,000
-42,286
| -43% | -$3.97M |
|
19
Community Health Systems
CYH
$412M
| $4.63M | 1.37% |
123,420
+40,187
| +48% | +$1.34M |
|
|
CYBX
20
DELISTED
CYBERONICS INC
CYBX
| $4.62M | 1.37% |
74,000
+10,246
| +16% | +$624K |
|
21
Merck
MRK
$363B
| $4.51M | 1.34% |
81,744
+1,415
| +2% | +$77.2K |
|
22
Bristol-Myers Squibb
BMY
$129B
| $4.12M | 1.22% |
85,000
-1,815
| -2% | -$89.4K |
|
|
MDVN
23
DELISTED
MEDIVATION, INC.
MDVN
| $4.01M | 1.19% |
104,000
-105,010
| -50% | -$3.54M |
|
24
McKesson
MCK
$102B
| $4M | 1.19% |
21,500
-5,120
| -19% | -$911K |
|
25
Insulet
PODD
$9.73B
| $3.97M | 1.18% |
100,000
+41,039
| +70% | +$1.58M |
|
Similar funds
JSC
PCI
SAM
PCM
BDP
GX
CIC
RCIM
Rhenman & Partners Asset Management's Q2 2014 Portfolio in Review
As of Q2 2014, Rhenman & Partners Asset Management held 109 positions worth $337M, up 1.2% from $333M the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Rhenman & Partners Asset Management withdrew a net $17.9M in Q2 2014, closing 13 positions and reducing 37 holdings. Its most notable exit was Pfizer, an estimated $11.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 83% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Rhenman & Partners Asset Management opened a new position in Vertex Pharmaceuticals worth $9.62M.
- Rhenman & Partners Asset Management's largest Q2 2014 buy was Vertex Pharmaceuticals: 101,600 shares worth $9.62M.
- Rhenman & Partners Asset Management added most to COVIDIEN PLC COM SHS NEW (IRELAND) in Q2 2014, an estimated $9.48M increase.
- Rhenman & Partners Asset Management's biggest Q2 2014 reduction was Regeneron Pharmaceuticals, cutting an estimated $9.87M.
- Rhenman & Partners Asset Management fully exited Pfizer in Q2 2014, selling an estimated $11.3M.
- Rhenman & Partners Asset Management's ten largest holdings make up 34% of its $337M portfolio in Q2 2014.
- Rhenman & Partners Asset Management opened 18 new positions and closed 13 in Q2 2014.
- Rhenman & Partners Asset Management's portfolio value rose 1.2% quarter-over-quarter to $337M.
Based on Rhenman & Partners Asset Management's 13F filing for Q2 2014, filed 31 Jul 2014.